Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. develops and commercializes products for major types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company leverages its Artificial Intelligence (AI)-driven Multi-Omics Engine™ to achieve this. Cardio aims to become a leading medical technology company for enabling improved prevention, early detection, and treatment of cardiovascular disease, transforming the approach from reactive to proactive. The company believes incorporating its solutions into routine primary care and prevention efforts can help alter the trajectory that nearly one in two Americans is expected to develop some form of cardiovascular disease by 2035. Cardio states it is the first company to develop and commercialize epigenetics-based clinical tests for cardiovascular disease, offering value propositions for patients, clinicians, hospitals/health systems, employers, and payors. Epigenetics is the study of how behaviors and environment can cause changes affecting gene function, which are reversible and do not alter DNA sequence but change how the body reads it. In 2021, Cardio launched its first clinical test, Epi+Gen CHD™, a three-year symptomatic CHD risk assessment clinical blood test targeting CHD events, including heart attacks. The initial commercialization strategy involved launching the test via telemedicine and in smaller provider practices, such as concierge medicine practices, due to the COVID-19 pandemic.